Press Release

CHOSA Oncology AB presents at Stora Aktiedagarna in Stockholm

Mar 07, 2023

CHOSA oncology AB ("CHOSA") announces today, March 7, 2023, that the company will present at Stora Aktiedagarna in Stockholm on March 14th, 2023.

CHOSA's CEO Peter Buhl will present the company at Stora Aktiedagarna in Stockholm on 14th March 2023.
The program and registration for this event takes place at:

CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of iCIP™.

About iCIP™
CHOSA Oncology is focused on late-stage clinical development of iCIP™ (LiPlaCis® and its DRP® companion diagnostic together) to which it has worldwide rights.  The cisplatin DRP is the only proven test to foresee and thereby select whom to treat and who will benefit from cisplatin. The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Even when lung cancer surgery is successful in removing all visible tumor, too many patients have a reemergence of the cancer. Cisplatin therapy after surgery is a gold standard which clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Tissue from the patient’s lung cancers were tested with the cisplatin DRP technology to get the DRP scores. A high cisplatin DRP score was directly linked to high cisplatin efficacy. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1. CHOSA has submitted phase 2b data from its iCIP study of late stage metastatic breast cancer patients to present at the ASCO conference 2023.

1)  Buhl et al PLOS One doi: 10.1371/journal.pone0194609

DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.